First Time Loading...
G

Glenmark Life Sciences Ltd
NSE:GLS

Watchlist Manager
Glenmark Life Sciences Ltd
NSE:GLS
Watchlist
Price: 805.7 INR -1.14% Market Closed
Updated: Apr 29, 2024
Section:
 

Wall Street
Price Targets

GLS Price Targets Summary
Glenmark Life Sciences Ltd

Wall Street analysts forecast GLS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for GLS is 892.16 INR with a low forecast of 772.65 INR and a high forecast of 987 INR.

GLS Lowest Forecast
Wall Street Target
772.65 INR
4% Downside
GLS Average Forecast
Wall Street Target
892.16 INR
11% Upside
GLS Highest Forecast
Wall Street Target
987 INR
23% Upside
Lowest
Price Target
772.65 INR
4% Downside
Average
Price Target
892.16 INR
11% Upside
Highest
Price Target
987 INR
23% Upside
Glenmark Life Sciences Ltd Competitors:
Price Targets
N
603538
Ningbo Menovo Pharmaceutical Co Ltd
62% Upside
ALKEM
Alkem Laboratories Ltd
0% Downside
HCM
HUTCHMED (China) Ltd
33% Upside
C
300765
CSPC Innovation Pharmaceutical Co Ltd
49% Upside
N
603538
Ningbo Menovo Pharmaceutical Co Ltd
62% Upside
ALKEM
Alkem Laboratories Ltd
0% Downside
HCM
HUTCHMED (China) Ltd
33% Upside
C
300765
CSPC Innovation Pharmaceutical Co Ltd
49% Upside
234080
JW Life Science Corp
47% Upside
INDOCO
Indoco Remedies Ltd
20% Upside
O
ORNBV
Orion Oyj
15% Upside
185750
Chong Kun Dang Pharmaceutical Corp
34% Upside

Revenue
Forecast

Revenue Estimate
Glenmark Life Sciences Ltd

For the last 3 years the compound annual growth rate for Glenmark Life Sciences Ltd's revenue is 12%. The projected CAGR for the next 3 years is 12%.

12%
Past Growth
12%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Glenmark Life Sciences Ltd

For the last 3 years the compound annual growth rate for Glenmark Life Sciences Ltd's operating income is 11%. The projected CAGR for the next 3 years is 16%.

11%
Past Growth
16%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Glenmark Life Sciences Ltd

For the last 3 years the compound annual growth rate for Glenmark Life Sciences Ltd's net income is 14%. The projected CAGR for the next 3 years is 13%.

14%
Past Growth
13%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

See Also

Summary
GLS intrinsic value, competitors valuation, and company profile.
DCF Valuation
GLS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
GLS stock valuation using valuation multiples.
Wall Street Estimates
GLS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
GLS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is GLS's stock price target?
Price Target
892.16 INR

According to Wall Street analysts, the average 1-year price target for GLS is 892.16 INR with a low forecast of 772.65 INR and a high forecast of 987 INR.

What is Glenmark Life Sciences Ltd's Revenue forecast?
Projected CAGR
12%

For the last 3 years the compound annual growth rate for Glenmark Life Sciences Ltd's revenue is 12%. The projected CAGR for the next 3 years is 12%.

What is Glenmark Life Sciences Ltd's Operating Income forecast?
Projected CAGR
16%

For the last 3 years the compound annual growth rate for Glenmark Life Sciences Ltd's operating income is 11%. The projected CAGR for the next 3 years is 16%.

What is Glenmark Life Sciences Ltd's Net Income forecast?
Projected CAGR
13%

For the last 3 years the compound annual growth rate for Glenmark Life Sciences Ltd's net income is 14%. The projected CAGR for the next 3 years is 13%.

ALPHA SPREAD
Join more than 132,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.